SCHEMBL1702967

SCHEMBL1702967

Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 1.00
FLT3 P36888 12/20 1.00
KIT P10721 11/20 1.00
FLT1 P17948 8/20 1.00
CSF1R P07333 7/20 1.00
FLT4 P35916 7/20 1.00
LYN P07948 6/20 1.00
BLK P51451 6/20 1.00
LCK P06239 5/20 1.00
DYRK3 O43781 4/20 1.00
ROCK2 O75116 4/20 1.00
RET P07949 4/20 1.00
MET P08581 4/20 1.00
FGFR1 P11362 4/20 1.00
RPS6KB1 P23443 4/20 1.00
EPHA2 P29317 4/20 1.00
FRK P42685 4/20 1.00
CSNK1D P48730 4/20 1.00
IRAK1 P51617 4/20 1.00
CSNK1G2 P78368 4/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13523215 0.91 KDR (0.83) KDRFLT3KITFLT1CSF1R
SCHEMBL419771 0.89 KDR (1.00) KDRFLT3KITFLT1CSF1R
SCHEMBL1702965 0.88 KDR (0.79) KDRFLT3KITFLT1CSF1R
SCHEMBL1703074 0.88 KDR (0.78) KDRFLT3KITFLT1CSF1R
SCHEMBL1703600 0.88 KDR (0.78) KDRFLT3KITFLT1CSF1R
SCHEMBL1702841 0.85 KDR (0.78) KDRFLT3KITFLT1CSF1R
SCHEMBL1702898 0.85 KDR (1.00) KDRFLT3KITFLT1CSF1R
SCHEMBL3848792 0.83 KDR (0.70) KDRFLT3KITFLT1CSF1R
SCHEMBL1702951 0.82 KDR (0.80) KDRFLT3KITFLT1CSF1R
SCHEMBL2818029 0.81 KIT (0.74) KDRFLT3KITFLT1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP claimed
EP-1807424-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-18 EP claimed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US claimed
WO-2006050109-A2 NOVEL KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-05-11 WO claimed
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP disclosed
US-7812166-B2 Kinase inhibitors ABBOTT LABORATORIES (US) 2010-10-12 US disclosed
US-20100004306-A1 PIGF-1 Assay and kits and components thereof ABBOTT LABORATORIES (US) 2010-01-07 US disclosed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178378-A1 Novel kinase inhibitors ABL1, MAP3K19, MAP3K20 KDR 434/4885FLT3 79/4885KIT 426/4885
US-20100004306-A1 PIGF-1 Assay and kits and components thereof PGF, FLT1, HDGF KDR 9/4885FLT3 773/4885KIT 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.